1Ginsberg RJ, Vokes EE, Raben A. Non-small-cell lung cancer[A]. De Vita JI, Hellman S, Rosenberg SR.Cancer: principles and Practice of Oncology[M]. 5th edition, Philadelphia, Pensylvania: Lippincott-Raven,1997:858-911.
2Belani CP, Natale RB, Lee JS, et al. Randomized phase Ⅲ trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small-cell lung cancer(Meeting Abstr)[J]. Proc Am Soc Clin Oncol,1998,17: 455-458.
3Belani CP, Aisner J, Hiponia D, et al. Paclitaxel and carboplatin with concurrent thoracic radiotherapy for regionally advanced non-small-cell cancer (NSCLC)(Meeting Abstr)[J].Proc Ann Meet Am Soc Clin Oncol,1996,15:A1201.
4Kosmidis P ,Mylonakis N, Skarlos D , et al. Paclitaxe(175mg/m2) plus carboplatin (6 AUC) versus Paclitaxel (225mg/m2) plus carboplatin (6 AUC ) in advanced non-small-cell cancer(NSCLC): a multicenter randomized trail. Hellenic Cooperative Oncology Group (
5Chen YM, Perng RP, Lee YC, et al. Paclitaxel plus carboplatin compared with paclitaxel plus gemcitabine shows similar efficacy while more cost-effective: a randomized phase Ⅱ study of combination chemotherapy against inoperable non-small-cell lung cancer
